Picture of model of urban architecture

Open Access research that is exploring the innovative potential of sustainable design solutions in architecture and urban planning...

Strathprints makes available scholarly Open Access content by researchers in the Department of Architecture based within the Faculty of Engineering.

Research activity at Architecture explores a wide variety of significant research areas within architecture and the built environment. Among these is the better exploitation of innovative construction technologies and ICT to optimise 'total building performance', as well as reduce waste and environmental impact. Sustainable architectural and urban design is an important component of this. To this end, the Cluster for Research in Design and Sustainability (CRiDS) focuses its research energies towards developing resilient responses to the social, environmental and economic challenges associated with urbanism and cities, in both the developed and developing world.

Explore all the Open Access research of the Department of Architecture. Or explore all of Strathclyde's Open Access research...

Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™

Italia, Jagdishbhai L and Sharp, Andrew and Carter, Katharine C and Warn, Peter and Kumar, M N V Ravi (2011) Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™. PLoS One, 6 (10).

[img] PDF (Italia_etal_PLoSOne2011)
Italia_etal_PLoSOne2011.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (1MB)

Abstract

Background: Despite advances in the treatment, the morbidity and mortality rate associated with invasive aspergillosis remains unacceptably high (70–90%) in immunocompromised patients. Amphotericin B (AMB), a polyene antibiotic with broad spectrum antifungal activity appears to be a choice of treatment but is available only as an intravenous formulation; development of an oral formulation would be beneficial as well as economical. Methodology: Poly(lactide-co-glycolode) (PLGA) nanoparticles encapsulating AMB (AMB-NPs) were developed for oral administration. The AMB-NPs were 113±20 nm in size with ~70% entrapment efficiency at 30% AMB w/w of polymer. The in vivo therapeutic efficacy of oral AMB-NPs was evaluated in neutropenic murine models of disseminated and invasive pulmonary aspergillosis. AMB-NPs exhibited comparable or superior efficacy to that of Ambisome® or Fungizone™ administered parenterally indicating potential of NPs as carrier for oral delivery. Conclusions: The present investigation describes an efficient way of producing AMB-NPs with higher AMB pay-load and entrapment efficiency employing DMSO as solvent and ethanol as non-solvent. The developed oral formulation was highly efficacious in murine models of disseminated aspergillosis as well as an invasive pulmonary aspergillosis, which is refractory to treatment with IP Fungizone™and responds only modestly to AmBisome®.